Department of Radiation Oncology, BC Cancer Agency, Vancouver, British Columbia V5Z 4E6, Canada.
Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1177-84. doi: 10.1016/j.ijrobp.2009.03.013. Epub 2009 Jun 27.
Volumetric modulated arc therapy (VMAT), the predecessor to Varian's RapidArc, is a novel extension of intensity-modulated radiotherapy (IMRT) wherein the dose is delivered in a single gantry rotation while the multileaf collimator leaves are in motion. Leaf positions and the weights of field samples along the arc are directly optimized, and a variable dose rate is used. This planning study compared seven-field coplanar IMRT (cIMRT) with VMAT for high-grade gliomas that had planning target volumes (PTVs) overlapping organs at risk (OARs).
10 previously treated patients were replanned to 60 Gy in 30 fractions with cIMRT and VMAT using the following planning objectives: 98% of PTV covered by 95% isodose without violating OAR and hotspot dose constraints. Mean OAR doses were maximally decreased without reducing PTV coverage or violating hotspot constraints. We compared dose-volume histogram data, monitor units, and treatment times.
There was equivalent PTV coverage, homogeneity, and conformality. VMAT significantly reduced maximum and mean retinal, lens, and contralateral optic nerve doses compared with IMRT (p < 0.05). Brainstem, chiasm, and ipsilateral optic nerve doses were similar. For 2-Gy fractions, mean monitor units were as follows: cIMRT = 789 +/- 112 and VMAT = 363 +/- 45 (relative reduction 54%, p = 0.002), and mean treatment times (min) were as follows: cIMRT = 5.1 +/- 0.4 and VMAT = 1.8 +/- 0.1 (relative reduction 65%, p = 0.002).
Compared with cIMRT, VMAT achieved equal or better PTV coverage and OAR sparing while using fewer monitor units and less time to treat high-grade gliomas.
容积旋转调强弧形治疗(VMAT)是瓦里安公司 RapidArc 的前身,是调强放射治疗(IMRT)的一种新扩展,其中剂量在单个旋转机架时传递,同时多叶准直器叶片处于运动状态。直接优化叶片位置和沿弧的场样本权重,并使用可变剂量率。本研究比较了计划靶区(PTV)与危及器官(OAR)重叠的高级别胶质瘤的七野共面调强放疗(cIMRT)与 VMAT。
对 10 例先前接受治疗的患者进行再计划,采用 cIMRT 和 VMAT 以 60Gy/30 次分割进行治疗,使用以下计划目标:98%的 PTV 由 95%的等剂量线覆盖,不违反 OAR 和热点剂量限制。在不降低 PTV 覆盖率或违反热点限制的情况下,最大限度地降低平均 OAR 剂量。我们比较了剂量-体积直方图数据、监测器单位和治疗时间。
PTV 覆盖率、均匀性和适形性相当。与 IMRT 相比,VMAT 显著降低了最大和平均视网膜、晶状体和对侧视神经剂量(p < 0.05)。脑干、视交叉和同侧视神经剂量相似。对于 2Gy 剂量,平均监测器单位如下:cIMRT = 789 +/- 112 和 VMAT = 363 +/- 45(相对减少 54%,p = 0.002),平均治疗时间(分钟)如下:cIMRT = 5.1 +/- 0.4 和 VMAT = 1.8 +/- 0.1(相对减少 65%,p = 0.002)。
与 cIMRT 相比,VMAT 在治疗高级别胶质瘤时,达到了相等或更好的 PTV 覆盖率和 OAR 保护,同时使用更少的监测器单位和更少的治疗时间。